Rasenack, Jens; Zeuzem, Stefan; Feinman, S. Victor; … - In: PharmacoEconomics 21 (2003) 5, pp. 341-349
Background: Use of unmodified interferon alpha-2a in chronic hepatitis C is associated with impaired health-related quality of life during therapy. Treatment with peginterferon alpha-2a (40kD) provides an improved sustained response over unmodified interferon alpha-2a. Objectives: To compare...